ATP-citrate lyase (ACLY) inhibitors as therapeutic agents: a patenting perspective

References

• Fan F, Williams HJ, Boyer JG, et al. On the catalytic mechanism of human ATP citrate lyase. Biochemistry. 2012;51(25):5198–5211.
   PubMed Web of Science ®Google Scholar
• Linn TC, Srere PA. Binding of ATP citrate lyase to the microsomal fraction of rat liver. J Biol Chem. 1984;259(21):13379–13384.
   PubMed Web of Science ®Google Scholar
• Wellen KE, Hatzivassiliou G, Sachdeva UM, et al., ATP-citrate lyase links cellular metabolism to histone acetylation. Science. 2009;324(5930):1076–1080.
   PubMed Web of Science ®Google Scholar
• Elshourbagy NA, Near JC, Kmetz PJ, et al. Rat ATP citrate-lyase. Molecular cloning and sequence analysis of a full-length cDNA and mRNA abundance as a function of diet, organ, and age. J Biol Chem. 1990;265(3):1430–1435.
   PubMed Web of Science ®Google Scholar
• MacDonald MJ, Longacre MJ, Warner TF, et al. High level of ATP citrate lyase expression in human and rat pancreatic islets. Horm Metab Res. 2013;45(5):391–393.
   PubMed Web of Science ®Google Scholar
• Vzw VIB, Universiteit Gent. Crystal structure of ATP citrate lyase and uses thereof. WO2020182615. 2020.
   Google Scholar
• Verschueren KHG, Blanchet C, Felix J, et al. Structure of ATP citrate lyase and the origin of citrate synthase in the Krebs cycle. Nature. 2019;568(7753):571–575.
   PubMed Web of Science ®Google Scholar
• Wei X, Schultz K, Bazilevsky GA, et al. Molecular basis for acetyl-CoA production by ATP-citrate lyase. Nat Struct Mol Biol. 2020;27(1):33–41.
   PubMed Web of Science ®Google Scholar
• Wei J, Leit S, Kuai J, et al. An allosteric mechanism for potent inhibition of human ATP-citrate lyase. Nature. 2019;568(7753):566–570.
   PubMed Web of Science ®Google Scholar
• Moffett JR, Puthillathu N, Vengilote R, et al. Acetate revisited: a key biomolecule at the nexus of metabolism, epigenetics and oncogenesis-Part 1: acetyl-CoA, acetogenesis and acyl-coa short-chain synthetases. Front Physiol. 2020;11:580167.
   PubMed Web of Science ®Google Scholar
• Galdieri L, Zhang T, Rogerson D, et al. Protein acetylation and acetyl coenzyme a metabolism in budding yeast. Eukaryot Cell. 2014;13(12):1472–1483.
   PubMedGoogle Scholar
• Mariño G, Pietrocola F, Madeo F, et al. Caloric restriction mimetics: natural/physiological pharmacological autophagy inducers. Autophagy. 2014;10(11):1879–1882.
   PubMed Web of Science ®Google Scholar
• Koendjbiharie JG, van Kranenburg R, Kengen SWM. The PEP-pyruvate-oxaloacetate node: variation at the heart of metabolism. FEMS Microbiol Rev. 2021;45(3):fuaa061.
   PubMed Web of Science ®Google Scholar
• Granchi C. ATP citrate lyase (ACLY) inhibitors: an anti-cancer strategy at the crossroads of glucose and lipid metabolism. Eur J Med Chem. 2018;157:1276–1291.
   PubMed Web of Science ®Google Scholar
• Feng X, Zhang L, Xu S, et al. ATP-citrate lyase (ACLY) in lipid metabolism and atherosclerosis: an updated review. Prog Lipid Res. 2020;77:101006.
   PubMed Web of Science ®Google Scholar
• Verberk SGS, Kuiper KL, Lauterbach MA, et al. The multifaceted therapeutic value of targeting ATP-citrate lyase in atherosclerosis. Trends Mol Med. 2021;27(12):1095–1105.
   PubMed Web of Science ®Google Scholar
• Zaidi N, Swinnen JV, Smans K. ATP-citrate lyase: a key player in cancer metabolism. Cancer Res. 2012;72(15):3709–3714.
   PubMed Web of Science ®Google Scholar
• Icard P, Wu Z, Fournel L, et al. ATP citrate lyase: a central metabolic enzyme in cancer. Cancer Lett. 2020;471:125–134.
   PubMed Web of Science ®Google Scholar
• Burke AC, Huff MW. ATP-citrate lyase: genetics, molecular biology and therapeutic target for dyslipidemia. Curr Opin Lipidol. 2017;28(2):193–200.
   PubMed Web of Science ®Google Scholar
• Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309–314.
   PubMed Web of Science ®Google Scholar
• de la Cruz-lópez Kg, Castro-Muñoz LJ, Reyes-Hernández DO, et al. Lactate in the regulation of tumor microenvironment and therapeutic approaches. Front Oncol. 2019;9:1143.
   PubMed Web of Science ®Google Scholar
• Cai L, Ying M, Wu H. Microenvironmental factors modulating tumor lipid metabolism: paving the way to better antitumoral therapy. Front Oncol. 2021;11:777273.
   PubMed Web of Science ®Google Scholar
• Baenke F, Peck B, Miess H, et al. Hooked on fat: the role of lipid synthesis in cancer metabolism and tumour development. Dis Model Mech. 2013;6(6):1353–1363.
   PubMed Web of Science ®Google Scholar
• Hatzivassiliou G, Zhao F, Bauer DE, et al. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell. 2005;8(4):311–321.
   PubMed Web of Science ®Google Scholar
• Bauer DE, Hatzivassiliou G, Zhao F, et al. ATP citrate lyase is an important component of cell growth and transformation. Oncogene. 2005;24(41):6314–6322.
   PubMed Web of Science ®Google Scholar
• Liu Q, Ge W, Wang T, et al. High-throughput single-cell mass spectrometry reveals abnormal lipid metabolism in pancreatic ductal adenocarcinoma. Angew Chem Int Ed Engl. 2021;60(46):24534–24542.
   PubMed Web of Science ®Google Scholar
• Carrer A, Trefely S, Zhao S, et al. Acetyl-CoA Metabolism Supports Multistep Pancreatic Tumorigenesis. Cancer Discov. 2019;9(3):416–435.
   PubMed Web of Science ®Google Scholar
• Göttgens EL, van den Heuvel CN, de Jong MC, et al. ACLY (ATP Citrate Lyase) mediates radioresistance in head and neck squamous cell carcinomas and is a novel predictive radiotherapy biomarker. Cancers (Basel). 2019;11(12):1971.
   Web of Science ®Google Scholar
• Zhou Y, Bollu LR, Tozzi F, et al. ATP citrate lyase mediates resistance of colorectal cancer cells to SN38. Mol Cancer Ther. 2013;12(12):2782–2791.
   PubMed Web of Science ®Google Scholar
• Qian X, Hu J, Zhao J, et al. ATP citrate lyase expression is associated with advanced stage and prognosis in gastric adenocarcinoma. Int J Clin Exp Med. 2015;8(5):7855–7860.
   PubMed Web of Science ®Google Scholar
• Dai M, Yang B, Chen J, et al. Nuclear-translocation of ACLY induced by obesity-related factors enhances pyrimidine metabolism through regulating histone acetylation in endometrial cancer. Cancer Lett. 2021;513:36–49.
   PubMed Web of Science ®Google Scholar
• Wei X, Shi J, Lin Q, et al. Targeting ACLY attenuates tumor growth and acquired cisplatin resistance in ovarian cancer by inhibiting the PI3K-AKT pathway and activating the AMPK-ROS Pathway. Front Oncol. 2021;11:642229.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Zhou Q, Zhao C, et al. ATP citrate lyase inhibitor triggers endoplasmic reticulum stress to induce hepatocellular carcinoma cell apoptosis via p-eIF2α/ATF4/CHOP axis. J Cell Mol Med. 2021;25(3):1468–1479.
   PubMed Web of Science ®Google Scholar
• Han Q, Chen CA, Yang W, et al. ATP-citrate lyase regulates stemness and metastasis in hepatocellular carcinoma via the Wnt/β-catenin signaling pathway. Hepatobiliary Pancreat Dis Int. 2021;20(3):251–261.
   PubMed Web of Science ®Google Scholar
• Gu L, Zhu Y, Lin X, et al. The IKKβ-USP30-ACLY Axis Controls Lipogenesis and Tumorigenesis. Hepatology. 2021;73(1):160–174.
   PubMed Web of Science ®Google Scholar
• Chen Y, Li K, Gong D, et al. ACLY: a biomarker of recurrence in breast cancer. Pathol Res Pract. 2020;216(9):153076.
   PubMed Web of Science ®Google Scholar
• Guo W, Ma J, Yang Y, et al. ATP-Citrate Lyase epigenetically potentiates oxidative phosphorylation to promote melanoma growth and adaptive resistance to MAPK inhibition. Clin Cancer Res. 2020;26(11):2725–2739.
   PubMed Web of Science ®Google Scholar
• Wen J, Min X, Shen M, et al. ACLY facilitates colon cancer cell metastasis by CTNNB1. J Exp Clin Cancer Res. 2019;38(1):401.
   PubMed Web of Science ®Google Scholar
• Kumari R, Deshmukh RS, Das S. Caspase-10 inhibits ATP-citrate lyase-mediated metabolic and epigenetic reprogramming to suppress tumorigenesis. Nat Commun. 2019;10(1):4255.
   PubMedGoogle Scholar
• Wang Q, Jiang L, Wang J, et al. Abrogation of hepatic ATP-citrate lyase protects against fatty liver and ameliorates hyperglycemia in leptin receptor-deficient mice. Hepatology. 2009;49(4):1166–1175.
   PubMed Web of Science ®Google Scholar
• Guo L, Guo YY, Li BY, et al. Enhanced acetylation of ATP-citrate lyase promotes the progression of nonalcoholic fatty liver disease. J Biol Chem. 2019;294(31):11805–11816.
   PubMed Web of Science ®Google Scholar
• Rhee J, Solomon LA, DeKoter RP. A role for ATP Citrate Lyase in cell cycle regulation during myeloid differentiation. Blood Cells Mol Dis. 2019;76:82–90.
   PubMed Web of Science ®Google Scholar
• Santarsiero A, Convertini P, Todisco S, et al. ACLY nuclear translocation in human macrophages drives proinflammatory gene expression by NF-κB acetylation. Cells. 2021;10(11):2962.
   PubMed Web of Science ®Google Scholar
• de Goede Ke, Verberk SGS, Baardman J, et al. Myeloid-Specific acly deletion alters macrophage phenotype in vitro and in vivo without affecting tumor growth. Cancers (Basel). 2021;13(12):3054.
   PubMed Web of Science ®Google Scholar
• Baardman J, Verberk SGS, van der Velden S, et al. Macrophage ATP citrate lyase deficiency stabilizes atherosclerotic plaques. Nat Commun. 2020;11(1):6296.
   PubMed Web of Science ®Google Scholar
• Bazilevsky GA, Affronti HC, Wei X, et al. ATP-citrate lyase multimerization is required for coenzyme-A substrate binding and catalysis. J Biol Chem. 2019;294(18):7259–7268.
   PubMed Web of Science ®Google Scholar
• Srere PA. The citrate cleavage enzyme. I. Distribution and purification. J Biol Chem. 1959;234:2544–2547.
   PubMed Web of Science ®Google Scholar
• Zegzouti H, Zdanovskaia M, Hsiao K, et al. ADP-Glo: a bioluminescent and homogeneous ADP monitoring assay for kinases. Assay Drug Dev Technol. 2009;7(6):560–572.
   PubMed Web of Science ®Google Scholar
• Nimbus Artemis, Inc. ACLY inhibitors and uses thereof. WO2020097408. 2020.
   Google Scholar
• Smith-Kline Beecham PLC. Phenylderivative as inhibitors of ATP citrate lyase. WO9322304. 1993.
   Google Scholar
• Gribble AD, Ife RJ, Shaw A, et al. ATP-citrate lyase as a target for hypolipidemic intervention. 2. Synthesis and evaluation of (3R*,5S*)-ω-substituted-3-carboxy-3,5-dihydroxyalkanoic acids and their γ-lactone prodrugs as inhibitors of the enzyme in vitro and in vivo. J Med Chem. 1998;41(19):3582–3595.
   PubMed Web of Science ®Google Scholar
• Smith-Kline Beecham PLC. Phenylderivate as inhibitors of ATP citrate lyase. US5447954. 1995.
   Google Scholar
• The Trustees of the University of Pennsylvania. Compositions and methods for treating cancer. WO2004100885. 2004.
   Google Scholar
• Sullivan AC, Singh M, Srere PA, et al. Reactivity and inhibitor potential of hydroxycitrate isomers with citrate synthase, citrate lyase, and ATP citrate lyase. J Biol Chem. 1977;252(21):7583–7590.
   PubMed Web of Science ®Google Scholar
• INSERM (Institut National de la Santé et de la Recherche Médicale), Université Paris Descartes, Sorbonne Université, Université Paris Diderot – paris 7, Assistance Publique-Hôpitaux de Paris (APHP), Université Paris-Sud. Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers. WO2019175113. 2019.
   Google Scholar
• INSERM (Institut National de la Santé et de la Recherche Médicale) Assistance Publique-Hôpitaux de Paris (APHP), Université Paris Descartes, Université Pierre et Marie Curie (Paris 6), Université Paris Diderot – Paris 7 Université Paris-Sud, Institut Gustave Roussy, Centre National de la recherche scientifique (CNRS). Methods and pharmaceutical compositions for modulating autophagy in a subject in need thereof. WO2015049365. 2015.
   Google Scholar
• Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. Cell. 2011;147(4):728–741.
   PubMed Web of Science ®Google Scholar
• Dezima Pharma BV Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and an ATP citrate lyase inhibitor – AMPK activator. WO2017023165. 2017.
   Google Scholar
• Pinkosky SL, Filippov S, Srivastava RA, et al. AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. J Lipid Res. 2013;54(1):134–151.
   PubMed Web of Science ®Google Scholar
• Pinkosky SL, Newton RS, Day EA, et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun. 2016;7:13457.
   PubMed Web of Science ®Google Scholar
• Burke AC, Telford DE, Sutherland BG, et al. Bempedoic acid lowers low-density lipoprotein cholesterol and attenuates atherosclerosis in low-density lipoprotein receptor-deficient (LDLR± and LDLR-/-) yucatan miniature pigs. Arterioscler Thromb Vasc Biol. 2018;38(5):1178–1190.
   PubMed Web of Science ®Google Scholar
• Samsoondar JP, Burke AC, Sutherland BG, et al. Prevention of diet-induced metabolic dysregulation, inflammation, and atherosclerosis in Ldlr-/- mice by treatment with the ATP-Citrate lyase inhibitor bempedoic acid. Arterioscler Thromb Vasc Biol. 2017;37(4):647–656.
   PubMed Web of Science ®Google Scholar
• cited 2021 Dec 15. www.clinicaltrials.gov
   Google Scholar
• Esperion Therapeutics, Inc. Sustained release formulations of bempedoic acid. WO2019161307. 2019.
   Google Scholar
• Suzhou Lixin Pharmaceutical Co. Ltd. Green preparation of bempedoic acid. CN113149829. 2021.
   Google Scholar
• Esperion Therapeutics, Inc. Hydroxyl compounds and compositions for cholesterol management and related uses. WO2004067489. 2004.
   Google Scholar
• Shenzhen Targetrx Inc. Substituted pentadecanedioic acid compound and pharmaceutical composition and application thereof. CN110054562. 2019.
   Google Scholar
• Memorial Sloan Kettering Cancer Center. Inhibition of Acetyl-CoA metabolism for treatment and prevention of immune system diseases and disorders. WO2018053233. 2018.
   Google Scholar
• El Hassouni B, Granchi C, Vallés-Martí A, et al. The dichotomous role of the glycolytic metabolism pathway in cancer metastasis: interplay with the complex tumor microenvironment and novel therapeutic strategies. Semin Cancer Biol. 2020;60:238–248.
   PubMed Web of Science ®Google Scholar
• Li JJ, Wang H, Tino JA, et al. 2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors. Bioorg Med Chem Lett. 2007;17(11):3208–3211.
   PubMed Web of Science ®Google Scholar
• Granchi C. Discovery of allosteric inhibition of human ATP-citrate lyase. Trends Pharmacol Sci. 2019;40(6):364–366.
   PubMed Web of Science ®Google Scholar
• Artemis N, Inc. ACLY inhibitors and uses thereof. US20200157076. 2020.
   Google Scholar
• Banyu Pharma Co. Ltd. ATP-citrate lyase inhibiting substances of BE-063437 type and method for producing the same. JP2001261682. 2001.
   Google Scholar
• Univ. China Three Gorges CTGU. ACLY (ATP citrate lyase) inhibitor for broad-spectrum tumor cell proliferation resistance. CN109893523. 2019.
   Google Scholar
• Deng Z, Wong NK, Guo Z, et al. Dehydrocurvularin is a potent antineoplastic agent irreversibly blocking ATP-citrate lyase: evidence from chemoproteomics. Chem Commun (Camb). 2019;55(29):4194–4197.
   PubMed Web of Science ®Google Scholar
• Univ. Fudan. Diterpenoid compound in fir and preparation method and application thereof in pharmacy. CN111548255. 2020.
   Google Scholar
• Univ. Taizhou. Application of heptacodium miconioides extract in preparation of ATP citrate lyase inhibitor. CN112641819. 2021.
   Google Scholar
• Univ. Taizhou. Use of natural chlorogenic acid derivative in preparation of ATP-citrate lyase (ACL) inhibitor. CN112957352. 2021.
   Google Scholar
• Fudan University. Intermolecular adduct of different terpenes in pseudotsuga forrestii and preparation method and pharmaceutical application thereof. CN113402384. 2021.
   Google Scholar
• Xiong J, Zhou PJ, Jiang HW, et al. Forrestiacids A and B, pentaterpene inhibitors of ACL and Lipogenesis: extending the Limits of Computational NMR Methods in the structure assignment of complex natural products. Angew Chem Int Ed Engl. 2021;60(41):22270–22275.
   PubMed Web of Science ®Google Scholar
• Taizhou University. Natural triterpene-iridoid glycoside dimer hybrid and its preparation and use in preparation of ACL inhibitor. CN113563409. 2021.
   Google Scholar
• Bar-Tana J, Rose-Kahn G, Srebnik M. Inhibition of lipid synthesis by beta beta’-tetramethyl-substituted, C14-C22, alpha, omega-dicarboxylic acids in the rat in vivo. J Biol Chem. 1985;260(14):8404–8410.
   PubMed Web of Science ®Google Scholar
• Rose-Kahn G, Bar-Tana J. Inhibition of lipid synthesis by beta beta’-tetramethyl-substituted, C14-C22, alpha, omega-dicarboxylic acids in cultured rat hepatocytes. J Biol Chem. 1985;260(14):8411–8415.
   PubMed Web of Science ®Google Scholar
• Institute for Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center. PI3K/LYN-ACLY signaling inhibition. WO2020243063. 2020.
   Google Scholar
• Basappa J, Citir M, Zhang Q, et al. ACLY is the novel signaling target of PIP2/PIP3 and Lyn in acute myeloid leukemia. Heliyon. 2020;6(5):e03910.
   PubMed Web of Science ®Google Scholar
• The Board of Trustees of the Leland Stanford Junior University. Methods of identifying MYC-driven and lipogenesis-dependent neoplasms and methods of treating the same. WO2018170316. 2018.
   Google Scholar
• The Brigham and Women’s Hospital, Inc. Methods and compositions for the treatment of inflammatory diseases. WO2019074891. 2019.
   Google Scholar
• Merck Patent GMBH. Use of protein histidine phosphatase. WO02070676. 2002.
   Google Scholar
• Ajinomoto Co., Inc. Medicinal composition for inhibiting the expression of ATP-citrate lyase and use thereof. WO03099332. 2003.
   Google Scholar
• Ikenoue T, Akiyoshi M, Fujitani S, et al. Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine (A-4166). Br J Pharmacol. 1997;120(1):137–145.
   PubMed Web of Science ®Google Scholar
• Shanghai Inst. Biol. Sciences. Application of ACL on sieving drugs for preventing obesity-related metabolic disturbance diseases. CN101579351. 2008.
   Google Scholar
• Beth Israel deaconess medical center. Micro-RNA and obesity. WO2019178410. 2019.
   Google Scholar
• Zhao T, Liu YN, Sun XY, et al. Two New Oleanane-Triterpenoid Saponins from Clinopodium gracile. Chem Biodivers. 2021;18(11):e2100672.
   PubMed Web of Science ®Google Scholar
• Rodrigues T, Reker D, Schneider P, et al. Counting on natural products for drug design. Nat Chem. 2016;8(6):531–541.
   PubMed Web of Science ®Google Scholar
• Khwairakpam AD, Shyamananda MS, Sailo BL, et al. ATP citrate lyase (ACLY): a promising target for cancer prevention and treatment. Curr Drug Targets. 2015;16(2):156–163.
   PubMed Web of Science ®Google Scholar